It’s our mission to deliver innovative therapies to improve the lives of patients impacted by cancer and autoimmune diseases.

Learn more about MorphoSys’ agreement to acquire Constellation Pharmaceuticals and our strategic funding partnership with Royalty Pharma

CLICK HERE >
04/06/2021
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study...
02/06/2021
MorphoSys to Acquire Constellation Pharmaceuticals
02/06/2021
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into...
21/05/2021
MorphoSys To Participate in UBS Global Healthcare Conference
19/05/2021
MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO...
11/05/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND...
05/05/2021
MorphoSys AG Reports First Quarter 2021 Results
28/04/2021
Invitation to MorphoSys' First Quarter Results Conference Call on May...
19/04/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study...
15/03/2021
MorphoSys AG Presents Results for Full Year 2020

June 8, 2021
Fireside Chat
Goldman Sachs 42nd Annual Global Healthcare Conference

Full details